a PD-1 inhibitor

DRUG2 trials

Sponsors

Agenus Inc., Teon Therapeutics, Inc.

Conditions

Advanced CancerAdvanced Solid TumorCancerOncology

Phase 1

A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors

CompletedNCT05025085

Agenus Inc.Advanced Cancer

Start: 2021-10-04End: 2024-04-01Updated: 2025-10-15

TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)

TerminatedNCT05525455

Teon Therapeutics, Inc.Advanced Cancer, Advanced Solid Tumor, Cancer +1

Start: 2022-08-29End: 2023-09-07Updated: 2024-11-21